NEUROENDOCRINE NEOPLASMS
Clinical trials for NEUROENDOCRINE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASMS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in shrinking Tough-to-Treat lung and neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug called BI 764532 (obrixtamig) in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatment. The drug is designed to help the immune system attack cancer cells. The study aims to find the best…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
New hope for rare cancer: Real-World drug study launches
Disease control Recruiting nowThis study looks at how well the drug surufatinib works for people with advanced neuroendocrine tumors (a type of cancer) in real-life medical settings. About 350 adults will take the drug by mouth, either alone or with other treatments, and be monitored for tumor shrinkage, side…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for rare tumors: radioactive therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy targets tough neuroendocrine tumors
Disease control Recruiting nowThis early-phase study tests an experimental drug (BI 764532) added to standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC) whose tumors have a specific marker (DLL3). The main goals are to find safe dose levels and see if the combination helps shrink tum…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo shows promise for rare gut tumors
Disease control Recruiting nowThis study tests whether combining two drugs, Lutathera (a radioactive therapy) and Olaparib (a targeted pill), can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several months and be m…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New imaging study tracks cancer Drug's path in Hard-to-Treat tumors
Knowledge-focused Recruiting nowThis study is for adults with advanced small cell lung cancer or other neuroendocrine cancers that haven't responded to standard treatments. Researchers want to see how the experimental drug BI 764532 moves through the body and gets absorbed by tumors using special PET scans. Abo…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated May 19, 2026 11:59 UTC